2019
Octreotide, 40 years later
Publication
Publication
European Journal of Endocrinology , Volume 181 - Issue 5 p. R173- R183
Octreotide remains 40 years after its development a drug, which is commonly used in the treatment of acromegaly and GEP-NETs. Very little innovation that competes with this drug occurred over this period. This review discusses several aspects of 40 years of clinical use of octreotide, including the application of radiolabeled forms of the peptide.
Additional Metadata | |
---|---|
doi.org/10.1530/eje-19-0074, hdl.handle.net/1765/123285 | |
European Journal of Endocrinology | |
Organisation | Department of Internal Medicine |
Lamberts, S., & Hofland, L. (2019). Octreotide, 40 years later. European Journal of Endocrinology, 181(5), R173–R183. doi:10.1530/eje-19-0074 |